Senti Bio Amends Merger Proxy: Adds $2.5M Equity Commitment, $2M NSG Notes, and Reverse Split to Avert Nasdaq Delisting
SNTI is trading near its 52-week low of $0.331 (8.9% above the low) on light trading volume (0.2× avg).
Summary
Senti Bio's amended merger proxy adds a $2.5M Celadon equity commitment, completes the $6M Additional Notes funding, and seeks approval for a 1-for-20 to 1-for-50 reverse stock split to address two Nasdaq delisting notices.
Key Events · M&A and Partnerships · SNTI
-
Reverse Stock Split Proposed
Board seeks approval for a 1-for-20 to 1-for-50 reverse split to regain compliance with Nasdaq's $1.00 minimum bid price requirement after receiving a delisting notice on August 27, 2026.
-
Nasdaq Delisting Notices
Company received two Nasdaq notices on August 27, 2026: minimum bid price deficiency and stockholders' equity deficit of $3.4M as of June 30, 2026.
-
New Equity Commitment
A Celadon affiliate agreed on September 3, 2026 to purchase $2.5M of common stock at the Nasdaq Minimum Price at or around merger closing.
-
Additional Notes Funding Completed
NSG purchased $2.0M of Additional Notes on September 3, 2026, satisfying the remaining $6.0M Additional Funding obligation under the Merger Agreement.
Analysis · SNTI · Life Sciences
This amended proxy adds material new facts to the previously disclosed Celadon-led merger. The company now faces two Nasdaq delisting notices (minimum bid price and stockholders' equity) and is seeking approval for a 1-for-20 to 1-for-50 reverse stock split to regain compliance. It also discloses a new $2.5M equity commitment from a Celadon affiliate and the completion of the $6.0M Additional Notes funding via NSG's $2.0M purchase. These developments materially change the risk profile for existing shareholders: the reverse split is a survival mechanism, and the new financing deepens Celadon's control while providing near-term runway.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SNTI was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.6M. The 52-week trading range was $0.33 to $2.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.